WO2007129133A1 - Pommade ou crème utilisée dans le traitement par voie topique du psoriasis - Google Patents

Pommade ou crème utilisée dans le traitement par voie topique du psoriasis Download PDF

Info

Publication number
WO2007129133A1
WO2007129133A1 PCT/IB2006/001260 IB2006001260W WO2007129133A1 WO 2007129133 A1 WO2007129133 A1 WO 2007129133A1 IB 2006001260 W IB2006001260 W IB 2006001260W WO 2007129133 A1 WO2007129133 A1 WO 2007129133A1
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
cream
treatment
weight
ointment
Prior art date
Application number
PCT/IB2006/001260
Other languages
English (en)
Spanish (es)
Inventor
Abel Poleo Romero
Ruth Gaviria
Original Assignee
Abel Poleo Romero
Ruth Gaviria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abel Poleo Romero, Ruth Gaviria filed Critical Abel Poleo Romero
Priority to PCT/IB2006/001260 priority Critical patent/WO2007129133A1/fr
Publication of WO2007129133A1 publication Critical patent/WO2007129133A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • Psoriasis is a chronic dermatological disease that affects 2-3% of the world's population, whose etiology is not fully elucidated. Some doctors suggest that stress and its product cause excessive free radicals.
  • T lymphocytes are activated inappropriately, causing excessive proliferation of the epidermis that causes the characteristic psoriatic plaques.
  • vascular proliferation angiogenesis
  • psoriasis is characterized by epidermal hyperplasia, accumulation of neutrophils and T lymphocytes and vascular proliferation (Champ RDR. In: Psoriasis.
  • Metrotexate is a An oral antineoplastic drug that is used in cases of severe joint involvement (arthritic psoriasis) that can cause liver fibrosis and cirrhosis (GreavesMW, Weinstein GD. Nw Engl J Med 332: 381-388, 1995). Vitamin D analogues are less effective than corticosteroids. There is therefore a need to look for new effective products and without important side effects for the treatment of psoriasis.
  • the ideal antipsoriatic treatment would be one that simultaneously blocks the infiltration and activation of T-Imfocitos and angiogenesis and does not allow tissue damage to all skin layers such as the epidermis and dermis, observing a keratinocyte hyperativity.
  • EGF epidermal growth factor
  • FGF fibroblast growth factor
  • VEGF vascular endothelial growth factor
  • EGF Epidermal growth factor
  • FGF fibroblast growth factors
  • EGF EGF
  • FGF FGF
  • VEGF vascular endothelial growth factor
  • the present invention relates to a preparation based on plant extracts that has an antioxidant effect and is particularly useful in the treatment of psoriasis.
  • This object is achieved in accordance with the invention by providing a preparation characterized in that its active ingredients include a combination of biflavones from Pimenta racmosa, Cucumis Meló and Mimosa pudica.
  • the preparation is obtained by mixing the extracts of these plants as they contain important active ingredients and in particular flavonol glycosides, lactonic terpenes and flavones or dimeric biflavones.
  • Flavonol glycosides and lactonic terpenes are the active components of Pimena Racemosa extracts, antioxidants and powerful stimulants of nitric oxide and antagonists of the effective platelet aggregation factor (PAF).
  • PAF platelet aggregation factor
  • This cream treatment is highly enriched with the biflavone and glycoside component of flavonol and lactonic terpenes.
  • the biflavone component three biflavones have been identified in particular: these are, in particular, amentoflavone, bilobetin, and sciadopisitin; the three compounds mentioned differ only by the presence of methyl compounds in some positions and, like all flavones, they are powerful antioxidants.
  • they are characterized by their anti-phosphodiesterase, anti-inflammatory, vasculo-kinetic and anti-allergic properties.
  • Phosphodiesterases are cellular enzymes responsible for interaction with cyclic nucleotides so that they are linear. Cyclic nucleotides are involved as secondary messengers in the transmission of intercellular signals and are therefore responsible for some phenomena that are very important from a biochemical point of view. They help in the visual process, in the relaxation of smooth muscles and vascular movement in the capillary arterioles. More specifically, it is sufficient to say that in the inhibition of PDE that depends on cyclic AMPs, these biflavones demonstrate an IC-50 of 1.2 micromoles.
  • biflavones The anti-inflammatory properties of biflavones, and in particular those of amentoflavone, have been demonstrated both in vitro, measuring the interaction of these biflavones with cyclo-oxygenase, lipo-oxygenase and phospholipase A2, and in vivo, using various models of inflammation in animals (carrageenan edema, inflammation of Croton oil, etc.).
  • the anti-inflammatory action of biflavones was confirmed both in models using local application and in those administered intra-peritoneally. In these models, biflavones always demonstrated an anti-inflammatory action equivalent to that of indomethacin or prednisolone.
  • Biflavones also have clear antiallergic properties; inhibit the release of histamine by mast cells stimulated by allergens: thereby reducing or counteracting the formation of edemas that result from vasodilation and increases in vascular permeability.
  • the activity of the aforementioned biflavones is used, in combination with glycosides of flavonol and lactonic terpenes.
  • Leucoanthocyanins are procyanidol oligomers derived from condensation monomers of flavan-3-oles and flavan-3,4-diols, these being free or esterified
  • the therapeutic efficacy of the ointment of the invention has been assessed in 60 psoriatic patients of both sexes who did not receive any antipsoriatic treatment two weeks before starting treatment with the ointment object of the invention.
  • the study was conducted in accordance with the standards of the Declaration of Helsinki. The patient was instructed to use it three times a day for a period of 6 months, with a 100% improvement in a total of 59 patients.
  • the cream is prepared as follows:
  • 25% moisturizing base cream consisting of:
  • Cetyl alcohol (2.5% by weight), Stearyl alcohol (2.5% by weight), liquid petrolatum (30% by weight), petroleum jelly (20% by weight) Span (5% by weight) and distilled water (c.s.p. 100 g).
  • the ointment of the invention can be prepared by a method comprising mixing the aforementioned compounds, in the appropriate amounts, to obtain the indicated weight ratio, by stirring, until the homogeneous ointment is obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une pommade ou une crème utilisée dans le traitement par voie topique du psoriasis, contenant des antioxydants d'origine végétale provenant de Cucumis melo, Pimenta racemosa et Mimosa pudica. Le produit est complété avec une crème de base hydratante contenant, parmi d'autres composants, de l'alcool cétylique, de l'alcool stéarylique, de la vaseline liquide, de la vaseline filante et de l'eau distillée.
PCT/IB2006/001260 2006-05-08 2006-05-08 Pommade ou crème utilisée dans le traitement par voie topique du psoriasis WO2007129133A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/001260 WO2007129133A1 (fr) 2006-05-08 2006-05-08 Pommade ou crème utilisée dans le traitement par voie topique du psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/001260 WO2007129133A1 (fr) 2006-05-08 2006-05-08 Pommade ou crème utilisée dans le traitement par voie topique du psoriasis

Publications (1)

Publication Number Publication Date
WO2007129133A1 true WO2007129133A1 (fr) 2007-11-15

Family

ID=38667474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001260 WO2007129133A1 (fr) 2006-05-08 2006-05-08 Pommade ou crème utilisée dans le traitement par voie topique du psoriasis

Country Status (1)

Country Link
WO (1) WO2007129133A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153161A1 (fr) * 2011-05-12 2017-04-12 B.R.A.I.N. Biotechnology Research And Information Network AG Inhibiteurs de trpa1 à petite molécule

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806098A1 (de) * 1988-02-26 1989-09-07 Winfried Gaiser Prokamillan
RO109605B1 (ro) * 1994-06-20 1995-04-28 Gheorghe Dumitru Compoziție medicamentoasă, cu acțiune antipsoriazică
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
ES2158054T3 (es) * 1994-03-03 2001-09-01 Bio Obtention Sc Extracto proteinico de cucumis melo con actividad antioxidante y procedimiento de preparacion, composicion cosmetica o farmaceutica o composicion alimenticia que contienen dicho extracto.
US20040081681A1 (en) * 2002-10-25 2004-04-29 Jacob Vromen Formulations for topical delivery of bioactive substances and methods for their use
EP1604647A1 (fr) * 2004-05-12 2005-12-14 Ichimaru Pharcos Co., Ltd. Composition cosmétique comprenant un polymère à base de polyorganosiloxane et d' epsilon-polylysine, ainsi qu'un polyol, et sa fabrication

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806098A1 (de) * 1988-02-26 1989-09-07 Winfried Gaiser Prokamillan
ES2158054T3 (es) * 1994-03-03 2001-09-01 Bio Obtention Sc Extracto proteinico de cucumis melo con actividad antioxidante y procedimiento de preparacion, composicion cosmetica o farmaceutica o composicion alimenticia que contienen dicho extracto.
RO109605B1 (ro) * 1994-06-20 1995-04-28 Gheorghe Dumitru Compoziție medicamentoasă, cu acțiune antipsoriazică
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US20040081681A1 (en) * 2002-10-25 2004-04-29 Jacob Vromen Formulations for topical delivery of bioactive substances and methods for their use
EP1604647A1 (fr) * 2004-05-12 2005-12-14 Ichimaru Pharcos Co., Ltd. Composition cosmétique comprenant un polymère à base de polyorganosiloxane et d' epsilon-polylysine, ainsi qu'un polyol, et sa fabrication

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ M.A. ET AL.: "Anti-inflammatory activity of abietic acid, a diterpene isolated from Pimenta racemosa var. grissea", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 53, no. 6, 2001, pages 867 - 872 *
GARCIA D. ET AL.: "Gas chromatographic-mass spectrometry study of the essential oils of Pimenta racemosa var. terebinthina and Pimenta racemosa var. grisea", ZEITSCHRIFT NATURFORSCHUNG C, JOURNAL OF BIOSCIENCES, vol. 57, no. 1/2, 2002, pages 449 - 451 *
STOB F. ET AL.: "Novel antioxidants: new strategies in product stabilization and skin protection", SEIFEN, OLE, FETTE, WACHSE, vol. 124, no. 10, 1998, pages 604 - 613, XP001106542 *
TORNOS MAURY M.P.: "Aportacion al conocimiento de la flora medica caribena: estudio de Pimenta racemosa var. grisea (Kiaskov) Fosberg", UNIVERSIDAD DE SEVILLA, 2001, Retrieved from the Internet <URL:http://www.mcu.es/TESEO/teseo.html> *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153161A1 (fr) * 2011-05-12 2017-04-12 B.R.A.I.N. Biotechnology Research And Information Network AG Inhibiteurs de trpa1 à petite molécule
US10000438B2 (en) 2011-05-12 2018-06-19 B.R.A.I.N. Biotechnology Research And Information Network Ag Small molecule inhibitors of TRPA1

Similar Documents

Publication Publication Date Title
Süntar et al. Wound healing potential of Sambucus ebulus L. leaves and isolation of an active component, quercetin 3-O-glucoside
Ko et al. Eupafolin, a skin whitening flavonoid isolated from Phyla nodiflora, downregulated melanogenesis: Role of MAPK and Akt pathways
ES2600909T3 (es) Composiciones que contienen berberina o análogos de la misma para tratar rosácea o trastornos de la piel relacionados con enrojecimiento de la cara
Barku et al. Phytochemical screening and assessment of wound healing activity of the leaves of Anogeissus leiocarpus
KR100772575B1 (ko) 생약성분 추출물을 함유하는 피부 외용제 조성물
CA2883348C (fr) Composition comprenant de la dihydroquercetine, de l&#39;a-tocopherol et du bisabolol
CN101836944A (zh) 植物提取物的组合物及对皮肤美白保湿的应用
Tahir et al. Evaluation of topical red dragon fruit extract effect (hylocereus polyrhizus) on tissue granulation and epithelialization in Diabetes Mellitus (DM) and Non-DM Wistar Rats: Pre Eliminary Study
Akram et al. A newly synthesized macakurzin C-derivative attenuates acute and chronic skin inflammation: The Nrf2/heme oxygenase signaling as a potential target
US10765641B2 (en) Cosmetic composition comprising a combination of pongamia oil and 4-t-butylcyclohexanol for the treatment of rosacea
JP2007230977A (ja) 顆粒球・マクロファージコロニー刺激因子（ｇｍ−ｃｓｆ）産生抑制剤ｉｉ
Momtaz et al. Wound healing activity of the flowers of Lilium candidum L. in burn wound model in rats
Girish et al. Influence of Tinospora cordifolia on wound healing in albino rats
JP2020193227A (ja) 外用組成物
WO2007129133A1 (fr) Pommade ou crème utilisée dans le traitement par voie topique du psoriasis
Saha et al. Investigating wound healing potential of Typha angustata L. inflorescence in albino Wistar rats
KR102142461B1 (ko) 구상나무 추출물을 포함하는 피부 상태 개선용 조성물
Gangane et al. A Review of Anti-Inflammatory Phytoconstituents Used in Herbal Cosmeceuticals for the Treatment of Atopic Dermatitis
Shivhare et al. Healing potential of Trichosanthes dioica Roxb on burn wounds
CN106466261A (zh) 养生护肤组合物
KR20110097462A (ko) 산두근 추출물을 유효성분으로 함유하는 아토피 예방 또는 치료용 조성물 및 이의 제조방법
Semkina Ointments, gels, liniments, and creams containing phytopreparations (a review)
US20110135763A1 (en) Antiseptic formulation especially for prevention of complications associated with skin burns
ES2664930T3 (es) Composición adyuvante para uso tópico
Ullah et al. Medicinal benefits of lemon balm (Melissa officinalis) for human health

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06755877

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06755877

Country of ref document: EP

Kind code of ref document: A1